This study focuses on patients with relapsed/refractory multiple myeloma, a type of blood cancer that returns after previous treatment. The study evaluates a combination of several medications: belantamab mafodotin, pomalidomide, dexamethasone, and in some cases daratumumab. These medications work together to target and fight cancer cells in different ways.
The main purpose of this research is to determine if this combination of medications is safe and effective for patients whose disease has returned after receiving one to three previous treatments, particularly in cases where a medication called lenalidomide is no longer working. The study is divided into two parts, with the first part focusing on finding the right dose and checking safety, while the second part looks at how well the treatment works.
During the study, participants will receive the medications through different methods – some are given as capsules by mouth, while others are administered through injections into the veins or under the skin. The doctors will monitor patients’ responses to the treatment and check for any side effects, with particular attention to effects on vision. The study will continue to follow patients to measure how long the treatment remains effective and how it affects survival.
Greece 
